SIC
RNAC icon

SJS Investment Consulting’s Cartesian Therapeutics RNAC Stock Holding History

SJS Investment Consulting’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219 Buy
21
+19
+950% +$141 ﹤0.01% 2458
2026
Q1 		$13 Buy
+2
New +$14 ﹤0.01% 2410

Other funds holding RNAC

FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

SJS Investment Consulting's RNAC Position: Q2 2026 in Review

SJS Investment Consulting increased its Cartesian Therapeutics (RNAC) stake by 950% in Q2 2026, buying an estimated $141 and bringing the position to 21 shares worth $219. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

SJS Investment Consulting first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • SJS Investment Consulting held 21 shares of Cartesian Therapeutics worth $219 as of Q2 2026.
  • SJS Investment Consulting bought 19 Cartesian Therapeutics shares in Q2 2026, an estimated $141.
  • Cartesian Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2458 holding.
  • SJS Investment Consulting first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.